DEVICE AND METHOD OF PERSONALIZED MEDICINE

• US 20170000905A1
• Filed: 06/30/2015
• Published: 01/05/2017
• Est. Priority Date: 06/30/2015
• Status: Abandoned Application

• Current Assignee: Vium, Inc. (Recursion Pharmaceuticals, Inc.)
• Original Assignee: Mousera Inc. (Recursion Pharmaceuticals, Inc.)
• Inventors: Schaevitz, Laura, Betts-Lacroix, Jonathan
• Application Number:
  US14/788,118
• Publication Number:
  US 20170000905A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A01K 1/031 Cages for laboratory animals; Cages for measuring metabolism of animals
• CPC Class Codes: A01K 29/005 Monitoring or measuring activity, e.g. detecting heat or mating
• CPC Class Codes: A61K 49/0008 Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
• CPC Class Codes: G01N 33/493 urine
• CPC Class Codes: G01N 33/497 of gaseous biological material, e.g. breath

Abstract

The field of this invention is personalized medicine. A tissue sample is taken from a patient, optionally amplified, and injected into animals, such as mice in a vivarium. Animals receive one or more therapeutic treatments. Animal behaviors are collected, measured and timed using fully automatic, continuous monitoring using per-cage sensors, where behavior recording is free of human, manual actions. Observed behavior is consistent with healthy or unhealthy behaviors specific to the injection site, typically in a specific organ or location in an organ, such as the brain. The injection site may be consistent with the source site from the patient. Both positive and negative baseline behaviors are collected, typically using the same device or method. Treatment selection is responsive to differences between treated and untreated animals, and between treatments, comparing to both the positive and negative baselines, using multi-dimensional analysis, including side effects.

Claims

1. A method for the treatment of a first patient comprising the steps of:

accepting a first xenograft from a first location in the first patient comprising cells of a first neoplasm;

placing in a vivarium a first set of animals in one or more cages;

subdividing the first set of animals into one or more subsets;

identifying a negative phenotype;

wherein the negative phenotype comprises behaviors and physiological indicators that are consistent with the first set of animals receiving no placement of cells of the first xenograft and no therapeutic treatment;

placing at least a portion of the first xenograft in a first location in the brain of each animal (a “

subject animal”

) in the one or more subsets of animals;

wherein the first location in the brain is associated with a first known set of animal behaviors;

identifying a positive phenotype, wherein the positive phenotype comprises behaviors and physiological indicators that are compatible unhealthy functioning of the first location of the first organ of the first set of animals;

treating each of the one or more subsets with an associated treatment regimen, wherein the associated treatment regimen for each subset is unique;

aggregating, measuring and timing one or more phenotype of the one or more subsets of animals, the “

treatment phenotypes”

;

comparing the treatment phenotypes of each one or more subsets to both the negative baseline phenotype and the positive baseline phenotype;

selecting a regimen responsive to some combination of;

(a) (the least difference between the treatment phenotype and the negative baseline phenotype) and (b) (the largest difference between the treatment phenotype and the set of positive baseline phenotype), for each associated treatment phenotype associated with the regimen; and

treating the first patient with the selected regimen.

3. The method of claim 1, wherein:

the vivarium cages are free of electronic penetrations.

4. The method of claim 1, wherein:

the vivarium comprises communicating electronic sensors proximal to each cage and wherein the communicating electronic sensors communicate behaviors of animals only in the each cage, free of human manual action.

5. The method of claim 1, wherein:

the aggregating, measuring and timing one or more phenotype of animal behaviors step is automated; and

the aggregating, measuring and timing is free of manual, human action.

6. The method of claim 1, wherein:

the aggregating, measuring and timing one or more phenotype of animal behaviors step is continuous; and

the aggregating, measuring and timing is free of manual, human action.

7. The method of claim 1, wherein:

the aggregating, measuring and timing of the one or more phenotypes of animal behaviors step uses, at least in part, communicating electronic sensors that are mechanically independent of the proximal cage such that either the communicating electronic sensors or the proximal cage may be replaced without mechanically moving the proximal cage or the communicating electronic sensors, respectively.

8. The method of claim 1, wherein:

the aggregating, measuring and timing of the one or more phenotypes of animal behaviors step uses, at least in part, communicating electronic sensors; and

the communicating electronic sensors comprise a scale adapted to measure and wirelessly communicate an animal weight; and

the communicating electronic sensors comprise one or more automated animal ID sensors that communicate an animal ID; and

the method associates the communicated animal ID with the communicated animal weight so as to uniquely identify the weight of each animal in its animal cage; and

wherein the animal weight and animal ID are determined and communicated free of human manual action.

9. The method of claim 1, wherein:

the set of negative baseline animal behaviors is determined by the same system that observes the behavior of the treated animals.

10. The method of claim 1, wherein:

the identifying a negative phenotype step is performed using the same vivarium and a portion of the first set of animals as is used in the step;

placing in a vivarium a first set of animals.

11. The method of claim 1, wherein:

the identifying a positive phenotype step is performed using the same vivarium and a portion of the first set of animals as is used in the step;

placing in a vivarium a first set of animals.

12. The method of claim 1, wherein:

the placing at least a portion of the first xenograft in a first location in the brain of each animal step is performed by injection using a stereotaxic device.

13. The method of claim 1, wherein:

the first neoplasm type is glioblastoma.

14. The method of claim 1, wherein:

at least one treatment regimen comprises both a drug treatment and a non-drug treatment.

15. The method of claim 1, wherein:

the phenotypes comprise at least one physiological measurement of a component of a waste product of the animals and wherein the at least one physiological measurement is automated.

16. The method of claim 13, wherein:

the waste product is urine.

17. The method of claim 13, wherein:

the waste product is exhaled air.

18. The method of claim 1, wherein:

the first neoplasm type is free of a known biomarker.

19. The method of claim 1, wherein:

the first set of animals comprise an immune system compatible with the immune system of the first patient.

20. The method of claim 1, wherein:

the selecting a regimen step is responsive to both (a) and (b).

21. A system that implements the method of claim 1.

22. A device comprising:

a vivarium; and

a computer system;

wherein the above elements of the device are adapted to perform the method steps of claim 1 for those steps and those portions of steps that do not require human, manual operations.

2. The method of claim 2, wherein:

the subdividing step subdivides the first set of animals into at least two non-overlapping subsets;

the treating each of the one or more subsets with an associated treatment regimen uses two or more distinct, associated treatment regimens; and

the method further comprises a step of;

comparing an efficacy of each of the two or more associated treatment regimens with the other associated treatment regimens wherein the efficacies are responsive to (a) the treatment phenotypes, (b) the negative baseline phenotype, and (c) the positive baseline phenotype.